financetom
Personal Finance
financetom
/
Personal Finance
/
TATA AIG launches 'Health Supercharge' with sum insured ranging from ₹5 lakh to ₹20 lakh
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TATA AIG launches 'Health Supercharge' with sum insured ranging from ₹5 lakh to ₹20 lakh
Nov 29, 2023 9:31 AM

TATA AIG General Insurance Company has launched “Health Supercharge” with a sum insured ranging from ₹5 lakh to ₹20 lakh. Customers can choose from options of two plan variants (Value Plan and Geo Plan), basis their geographical location, and other optional benefits offered under the product as per one’s requirement.

Live TV

Loading...

Speaking about the new health insurance policy – TATA AIG Health Supercharge, Santosh Puri, Senior Vice President – Health Product & Process, TATA AIG General Insurance said, “With the launch of Health Supercharge, we will be able to provide policyholders with 5X more coverage for their well-being."

Key highlights of Tata AIG Health Supercharge include:

The product introduces an enhanced level of coverage through a 5X supercharge bonus. This policy offers on each renewal a bonus of 50% of base sum insured of the expiring policy and accumulating maximum bonus up to 500% of the base sum insured in any policy year irrespective of claims.

Families below the age of 40 years or below at the time of first policy inception can benefit from an extra 5% discount which is also applicable upon policy renewals, irrespective of claims, the insurance company said.

The policy offers tailored flexibility with two plan variants (Value Plan & Geo Plan), and optional benefits such as unlimited restore, reduction of Pre-Existing Disease (PED) waiting period for named ailments.

Preventive annual health check-up can be availed by the insured persons once in a policy year, irrespective of claims, by paying an additional premium.

(Edited by : Anshul)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Hold Opinion On Shares Of Amcor Plc
Research Alert: CFRA Maintains Hold Opinion On Shares Of Amcor Plc
May 26, 2025
02:00 PM EDT, 05/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target by $1 to $11, valuing AMCR at an EV/EBITDA of 9.2x our FY 26 EBITDA estimate, a discount to the weighted average (63% AMCR ownership...
Research Alert: CFRA Keeps Hold Opinion On Shares Of United Parks & Resorts Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of United Parks & Resorts Inc.
May 26, 2025
03:00 PM EDT, 05/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $3 to $52, based on an EV/EBITDA multiple of 8x, in line with its three-year average forward multiple. We lift our 2025 EPS estimate...
Research Alert: CFRA Keeps Hold Opinion On Shares Of Franklin Resources, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Franklin Resources, Inc.
May 26, 2025
02:55 AM EDT, 05/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price of $22, valuing BEN shares at 9.3x our FY 26 (Sep.) adj. EPS estimate of $2.37 (cut by $0.20) and at 10.6x our FY...
Research Alert: CFRA Retains Sell Opinion On Shares Of 10x Genomics, Inc.
Research Alert: CFRA Retains Sell Opinion On Shares Of 10x Genomics, Inc.
May 26, 2025
12:50 AM EDT, 05/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our target price at $7, based on our DCF analysis. We narrow our 2025 adjusted LPS view to -$0.56 from -$1.50 and our 2026 adjusted LPS estimate to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved